Targeted replacement of an immunoglobulin gene without endogenous and selectable residual sequences in mice

• US 6,570,061 B1
• Filed: 02/23/1995
• Issued: 05/27/2003
• Est. Priority Date: 08/25/1992
• Status: Expired due to Fees

• Current Assignee: Kolner Verein Zurforderung Der Immunologie
• Original Assignee: Kolner Verein Zurforderung Der Immunologie
• Inventors: Rajewsky, Klaus, Zou, Yong-Rui
• Primary Examiner(s): WEHBE, ANNE MARIE SABRINA
• Application Number:
  US08/403,416
• Time in Patent Office: 3,015 Days
• Field of Search: 435/69.1, 435/69.2, 435/69.3, 435/69.4, 435/69.6, 435/71.1, 435/172.3, 435/320.1, 435/326, 435/352, 435/354, 435/455, 435/463, 435/462, 435/325, 530/387.1, 800/2, 800/18, 800/21, 800/22, 800/25, 800/4, 800/6, 800/5, 800/24
• US Class Current: 800/18
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 67/0275 Genetically modified vertebrates, e.g. transgenic
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C12N 15/907 in mammalian cells

Abstract

Transgenic mice that produce high levels of humanized antibodies are described. Targeted gene replacement exchanges constant regions of the mouse immunoglobulin heavy and light chain genes with human genes, either through conventional gene targeting, or by use of the bacteriophage-derived Cre-loxP recombination system. The transgenic animals undergo antibody affinity maturation, and a class switch from the native immunoglobulin to the humanized form.

Claims

1. A method of producing a transgenic mouse having a genome comprising a targeted, functional replacement of a mouse immunoglobulin constant region gene segment with a human immunoglobulin constant region gene segment comprising, selecting a transgenic mouse comprising a targeted, functional replacement of the mouse immunoglobulin constant region gene segment with said human immunoglobulin constant region gene segment, wherein said mouse is the progeny of a surrogate mother that contained a mouse blastocyst comprising a mouse embryonic stem cell, wherein said mouse embryonic stem cell was transfected with a recombination vector comprising a human immunoglobulin constant region gene segment, DNA sequences homologous to the mouse immunoglobulin constant region gene segment, a selectable marker gene and recombinase recognition sites flanking said selectable marker gene, wherein said selectable marker gene is removed by a non-mammalian recombinase.

2. The method of claim 1 wherein said embryonic stem cell expresses a non-mammalian recombinase.

3. The method of claim 1 wherein said immunoglobulin constant region gene segment is a heavy chain gene.

4. The method of claim 1 wherein said immunoglobulin constant region gene segment is a light chain gene.

5. The method of claim 1 wherein said recombinase recognition site is loxP and said recombinase is Cre recombinase.

6. The method of claim 1 wherein said recombinase recognition site is frt and said recombinase is Flip recombinase.

7. The method of claim 1 wherein said human constant region gene segment is from the Cγ

1 gene.

8. The method of claim 1 wherein human constant region gene segment is from the Ck gene.

9. A transgenic mouse made by the method of claim 1 and progeny of said mouse, wherein said mouse and said progeny have a genome comprising a targeted, functional replacement of a mouse immunoglobulin constant region gene segment with a human immunoglobulin constant region gene segment, wherein the genome of said mouse and said progeny lack said selectable marker gene of said method of claim 1, and wherein said mouse or said progeny produces antibodies comprising a human constant region joined to a mouse variable region in response to an antigen.

10. A method of producing a transgenic mouse having a genome comprising a targeted, functional replacement of a mouse immunoglobulin constant region gene segment with a human immunoglobulin constant region gene segment comprising the steps of:

i) transferring a mouse blastocyst comprising a mouse embryonic stem cell into a surrogate mother, wherein said embryonic stem cell is transfected with a recombination vector comprising a human immunoglobulin constant region gene segment, DNA sequences homologous to the mouse immunoglobulin constant region gene segment, a selectable marker gene and recombinase recognition sites flanking said selectable marker gene, wherein said selectable marker gene is removed by a non-mammalian recombinase;

ii) selecting surrogate mother progeny comprising a targeted, functional replacement of the mouse immunoglobulin constant region gene segment with said human immunoglobulin constant region gene segment.

11. The method of claim 10 wherein said embryonic stem cell expresses a non-mammalian recombinase.

12. A transgenic mouse made by the method of claim 10 and progeny of said mouse, wherein said mouse and said progeny have a genome comprising a targeted, functional replacement of a mouse immunoglobulin constant region gene segment with a human immunoglobulin constant region gene segment, wherein the genome of said mouse and said progeny lack said selectable marker gene of said method of claim 10, and wherein said mouse or said progeny produces antibodies comprising a human constant region joined to a mouse variable region in response to an antigen.

13. A transgenic mouse, or progeny thereof, having a genome comprising a targeted, functional replacement of a mouse immunoglobulin constant region gene segment with a human immunoglobulin constant region gene segment, wherein said transgenic mouse produces antibodies comprising a human constant region joined to a mouse variable region in response to an antigen.

14. A transgenic mouse, and progeny of said mouse, wherein said mouse is made by mating a transgenic mouse according to claim 13 with another transgenic mouse according to claim 13, wherein said mouse has a genome comprising a targeted, functional replacement of a mouse immunoglobulin constant region gene segment with a human immunoglobulin constant region gene segment, and wherein said mouse or said progeny produce antibodies comprising a human constant region joined to a mouse variable region in response to an antigen.

15. The transgenic mouse of claim 13 wherein said immunoglobulin constant region gene segment is a light chain gene.

16. The transgenic mouse of claim 13 wherein said immunoglobulin constant region gene segment is a heavy chain gene.

17. The transgenic mouse according to claim 13 wherein said human immunoglobulin constant region gene segment is present on both chromosomes.

18. The transgenic mouse according to claim 13, wherein said antibodies comprising a human constant region joined to a mouse variable region are produced at levels of at least 50 μ

g/ml in said mouse serum.

19. The transgenic mouse according to claim 13, wherein said human immunoglobulin constant region gene segment is from the Cγ

1 gene.

20. The transgenic mouse according to claim 13, wherein said human immunoglobulin constant region gene segment is from the Ck gene and wherein said antibodies are produced at levels of at least 500 μ

g/ml in said mouse serum.

21. The transgenic mouse according to claim 13, wherein said mouse comprises a human Cκ

gene segment inserted at the locus for an endogenous mouse immunoglobulin light chain constant region gene segment on both chromosomes and a human Cγ

1 constant region gene segment, wherein said antibodies produced comprise domains from human Ck, and human Cγ

1.

22. A method for producing humanized antibodies in response to an antigen, comprising the step of selecting antibodies comprising a human constant region gene segment from a transgenic mouse immunized with said antigen, said mouse having a genome comprising a targeted, functional replacement of a mouse immunoglobulin constant region gene segment with a human immunoglobulin constant region gene segment, wherein said transgenic mouse produces antibodies comprising a human constant region joined to a mouse variable region in response to an antigen.

23. The method of claim 22 wherein said immunoglobulin constant region gene segment is a light chain gene.

24. The method of claim 22 wherein said immunoglobulin constant region gene segment is a heavy chain gene.

25. The method of claim 22 wherein said human immunoglobulin constant region gene segment is present on both chromosomes.

26. The method of claim 22, wherein said antibodies comprising a human constant region joined to a mouse variable region are produced at levels of at least 50 μ

g/ml in said mouse serum.

27. The method of claim 22, wherein said human immunoglobulin constant region gene segment is from the Cγ

1 gene.

28. The method of claim 22, wherein said human immunoglobulin constant region gene segment is from the Cκ

gene and wherein said antibodies are produced at levels of at least 500 μ

g/ml.

29. The method of claim 22, wherein said mouse comprises a human Ck gene segment inserted at the locus for an endogenous mouse immunoglobulin light chain constant region gene segment on both chromosomes and a human Cγ

1 constant region gene segment, wherein said antibodies produced comprise domains from human Ck, and human Cγ

1.

30. A method for producing humanized antibodies in response to an antigen, comprising the steps of:

i) immunizing a transgenic mouse with said antigen, said mouse containing a genome comprising a targeted, functional replacement of a mouse immunoglobulin constant region gene segment with a human immunoglobulin constant region gene segment, wherein said transgenic mouse produces antibodies comprising a human constant region joined to a mouse variable region in response to said antigen; and

ii) selecting antibodies comprising a human constant region gene segment.

31. A method of producing a transgenic mouse comprising a human immunoglobulin light chain gene segment and a human immunoglobulin heavy chain gene segment comprising mating a first transgenic mouse having a genome comprising a targeted, functional replacement of a mouse immunoglobulin constant region gene segment with a human immunoglobulin constant region gene segment, wherein in said first transgenic mouse, said human immunoglobulin constant region gene segment is from the Cγ

1 gene, with a second transgenic mouse having a genome comprising a targeted, functional replacement of a mouse immunoglobulin constant region gene segment with a human immunoglobulin constant region gene segment, wherein in said second transgenic mouse said human immunoglobulin constant region gene segment is from the Ck gene and selecting progeny that comprises a gene segment from the Cγ

1 gene and a gene segment from the Ck gene.